Qbrexza Approved to Treat Hyperhidrosis
June 28, 2018 – The U.S. FDA has approved Qbrexza™ (glycopyrronium) cloths, manufactured by Dermira, to treat patients who are least nine years old and have primary axillary hyperhidrosis (excessive underarm sweating).
An estimated 10 million people in the United States have primary axillary hyperhidrosis. In most cases, the condition is treated with an antiperspirant. The active ingredient in Qbrexza, glycopyrronium, works by reducing the body’s ability to sweat.
Patients prescribed Qbrexza should only use one cloth to wipe each underarm area a single time, once per day. The cloths are saturated with a 2.4% glycopyrronium solution. Patients must wash their hands immediately after handling the cloths, and avoid touching their eyes. Qbrexza should not be used on broken or irritated skin.
Dermira plans to launch the product in October 2018. Pricing plans have not yet been announced.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.